Public Discontent Over Anticoagulant Mounts As Number Of Xarelto Lawsuit Filings Grow

June 17, 2016 – – TheProductLawyers.com reports on the initial excitement over the release of Xarelto, a new-generation blood-thinning drug. The U.S. Food and Drug Administration (FDA) approved the drug in 2011 to treat knee and hip replacement surgery patients, as well as those suffering from a number of medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation, a common heart ailment. Xarelto was unlike other blood-thinning drugs before it because it allowed patients who took it more freedoms.

Since its release, however, the drug has become the focus of controversy on numerous fronts. First and foremost, over 3,400 lawsuits have been filed against the makers of the drug, Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation, and Bayer AG. This multitude of complaints has been consolidated into two primary groups. In Philadelphia, PA, the Court of Common Pleas consolidated over 600 cases in a mass tort program. In Louisiana, another group of more than 2,800 federal cases has been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) and assigned number 2592. The multidistrict litigation (MDL) has been placed under the administrative oversight of the Honorable Judge Eldon Fallon. The cases were consolidated in both of these instances due to similar allegations over the dangerous risks of the drug and the fact that the defendants were the same in all of the individual lawsuits filed.

Additionally, the controversy surrounding the drug has been compounded by two other factors. The first are the investigations currently underway related to the drug’s clinical trials and a medical device that has been alleged to be potentially defective which was used during the clinical trials. The other issue fanning the flames of discontent with Xarelto is the FDA’s issuance of two black box warnings for the drug. These warnings are very severe and are the harshest warnings that can be given to a product. These warnings could ultimately result in the product’s complete removal from the consumer market.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010791